QDELQuidelOrtho Corporation

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

In early August 2026, QuidelOrtho reported second-quarter 2026 results showing sales of US$630.9 million and a net loss of US$92.9 million, alongside narrower losses per share than a year earlier. However, for the first half of 2026, sales eased to US$1.25 billion and the company reduced its full-year revenue outlook to US$2.52–2.60 billion, highlighting softer expectations despite improving losses. With QuidelOrtho lowering its full-year 2026 revenue guidance, we’ll now examine how this...

QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how QuidelOrtho (NASDAQ:QDEL) and the rest of the healthcare equipment and supplies stocks fared in Q2.

QuidelOrtho’s second quarter results were met with a negative market reaction, reflecting investor concern over significant challenges in key markets. While management pointed to solid demand in North America and strong commercial execution in regions like Japan and Latin America, CEO Brian J. Blaser cited a “softer respiratory environment” and pronounced weakness in China as primary factors impacting performance. The company’s leadership was notably cautious, highlighting that China revenue fel

China headwinds and respiratory uncertainty weigh on full-year guidance.

The sharp reset in QuidelOrtho’s fair value estimate from US$20.50 to US$12.00 per share sits alongside analyst price targets that now cluster around the US$12 to US$18 range. Recent research has become more divided, with some firms lifting targets while holding Neutral ratings and others, such as JPMorgan at US$12, keeping a more cautious stance. As you read on, you will see how these shifting targets feed into the broader narrative around risk, execution, and what to watch next with...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) fell 21.3% in the afternoon session after the company slashed its full-year revenue and earnings forecast, overshadowing a second-quarter earnings beat.

QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.

US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index’s 23% return. A copy of the letter can be downloaded here. The second quarter results were a complete reversal of Q1 results, with the portfolio appreciating 23.0% (gross) and 23.3% (net), […]

Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.8% year on year to $630.9 million. On the other hand, the company’s full-year revenue guidance of $2.56 billion at the midpoint came in 5.4% below analysts’ estimates. Its non-GAAP profit of $0.13 per share was significantly above analysts’ consensus estimates.

Moby summary of QuidelOrtho Corporation's Q2 2026 earnings call

QuidelOrtho (NASDAQ:QDEL) reported second-quarter revenue growth despite continued pressure from China and a softer respiratory testing environment, while lowering its full-year outlook and withdrawing free cash flow guidance. Total second-quarter revenue was $631 million, up 2% on a constant-curre

QuidelOrtho (QDEL) delivered earnings and revenue surprises of +425.00% and +2.65%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) announced better-than-expected revenue in Q2 CY2026, with sales up 2.8% year on year to $630.9 million. On the other hand, the company’s full-year revenue guidance of $2.56 billion at the midpoint came in 5.4% below analysts’ estimates. Its non-GAAP profit of $0.13 per share was significantly above analysts’ consensus estimates.

Investors need to pay close attention to QDEL stock based on the movements in the options market lately.

QuidelOrtho stock has seen a steep share price decline over the past few years, yet the current valuation checks still lean toward the shares looking inexpensive on several measures. Over the last 5 years, QuidelOrtho shareholders have seen the stock fall about 88.5%, which means today’s price is being set after a long period of weak returns. Future revenue and margin progress can support the current price, while any setbacks in turning that into consistent cash flow remain a key risk for...

Align Technology shares rise after Q2 earnings and revenues beat estimates, fueled by record Clear Aligner shipments and wider non-GAAP margins.

What a brutal six months it’s been for QuidelOrtho. The stock has dropped 40.6% and now trades at $16.68, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.

QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 10.2% over the past six months while the S&P 500 was up 7.7%.

Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.